JAZZ Stock Risk & Deep Value Analysis

Jazz Pharmaceuticals PLC

Healthcare • Biotechnology

DVR Score

0.1

out of 10

Distressed

What You Need to Know About JAZZ Stock

We analyzed Jazz Pharmaceuticals PLC using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran JAZZ through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated Feb 25, 2026•Run Fresh Analysis →

How Risky Is JAZZ Stock?

Overall Risk

Moderate

Financial Risk

Low

Market Risk

Medium

Competitive Risk

High

Execution Risk

Medium

Regulatory Risk

High

What Are the Red Flags for JAZZ?

⚠
Disappointing Q4 2025 earnings or soft 2026 guidance (Early March 2026)
⚠
Negative clinical trial results for pipeline assets (Ongoing)
⚠
Increased generic competition or patent challenges for top-selling drugs (Ongoing)
⚠
Regulatory delays or outright rejection for new indications/pipeline drugs (Ongoing)

Unlock JAZZ Red Flags & Risk Warnings

Create a free account to see the full analysis

What Does Jazz Pharmaceuticals PLC (JAZZ) Do?

Market Cap

$10.34B

Sector

Healthcare

Industry

Biotechnology

Employees

2,800

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Visit Jazz Pharmaceuticals PLC Website

Is JAZZ Stock Undervalued?

Jazz Pharmaceuticals remains an established biopharmaceutical company with a robust portfolio in neuroscience and oncology, generating consistent cash flow and pursuing disciplined pipeline management. The company's focus on label expansions, lifecycle management, and incremental pipeline advancements aligns with stable, long-term growth, but fundamentally lacks the disruptive technology, entry into new massive markets, or early-stage blockbuster potential required for a 10x return within a 3-5 year timeframe for a company of its current market capitalization ($10.56B). No material changes have occurred since the last analysis on 2026-01-17 that would alter this core assessment, hence the score consistency.

Unlock the full AI analysis for JAZZ

Get the complete DVR score, risk analysis, and more

Does JAZZ Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Stable

Moat Sources

3 Identified

Intangible Assets/IPSwitching CostsRegulatory Advantages

Jazz's moat primarily stems from its patented drugs like Xywav and Epidiolex, and the high regulatory hurdles and specialized physician network required for its core markets. Switching costs exist for patients on effective, established treatments. However, this moat is constantly challenged by upcoming patent expirations and the threat of generic or biosimilar competition, limiting its long-term durability to roughly 10-15 years for individual products.

Moat Erosion Risks

•Loss of exclusivity for key patents, leading to generic erosion (e.g., Xyrem, Xywav in the mid-2030s)
•Development of superior, safer, or more convenient competing therapies by rivals
•Pricing pressures from payers and government entities

JAZZ Competitive Moat Analysis

What Could Drive JAZZ Stock Higher?

Near-Term (0-6 months)

•Q4 2025 Earnings Release and Full-Year 2026 Guidance (Estimated early March 2026)
•Potential label expansion approvals for key neuroscience assets (e.g., Xywav, Epidiolex) in new indications.

Medium-Term (6-18 months)

•Phase 3 clinical trial readouts for lead oncology or neuroscience pipeline candidates (e.g., JZP441, JZP324) (H2 2026 - H1 2027)
•International market expansion for Rylaze (as approved in Europe/other regions) (2027)

Long-Term (18+ months)

•Strategic M&A to augment neuroscience/oncology portfolio and mitigate patent cliff risks (2028+)
•Successful development and commercialization of next-generation sleep disorder treatments (2028+)

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for JAZZ?

✓
Successful late-stage pipeline readouts and new drug approvals for novel assets
✓
Management's strategy and execution regarding patent cliff mitigation and new product launches
✓
Any significant shifts in regulatory landscape or pricing environment

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for JAZZ (Jazz Pharmaceuticals PLC) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.